XLO

Xilio is a clinical-stage oncology company with no approved product; its FY2025 revenue of $43.8M (up 589.9%) is collaboration and license income from its AbbVie collaboration and Gilead license, not durable product sales, so the headline growth rate overstates the underlying business. The company remains deeply unprofitable — operating income of -$42.0M (-95.9% margin), net loss of -$35.0M, and a -99.3% ROE against an accumulated deficit of -$419M. This is a binary, catalyst-driven story where the fundamentals will be set by trial data, not by extrapolating the income statement.

The balance sheet is the reason this isn't an outright avoid. Cash of $138M sits against a market cap of just $52.9M, and reported FY2025 operating cash burn was only -$4.99M because collaboration upfronts largely offset the $56.0M gross R&D spend. That said, total liabilities of $119M (3.39x equity) — much of which is likely deferred collaboration revenue rather than debt — leave net cash of roughly $19M, so the 'trading below cash' hook is real on gross cash but thinner on a net basis. The $36.2M of potential Series C warrant proceeds is contingent on the stock clearing the $10.50 exercise price, above today's $9.15.